Angiotensin II receptor blockers, ACE inhibitors, lung function and percent emphysema; the MESA lung study Source: Annual Congress 2012 - Asthma and COPD: quality of life and comorbidities Year: 2012
A dual-acting muscarinic antagonist, ß2 -agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Association between cyclooxygenase inhibitor use and efficacy of immunotherapy: a retrospective study Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Cough among hypertensive patients treated with angiotensin convertase inhibitors. Reduction of its frequency by substitution of angiotensin convertase inhibitor with angiotensin receptor blocker. Results of non-interventional, observational postmarketing study Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
Use of short-acting beta-2 agonists (SABA) and exacerbations in a nationwide Swedish asthma cohort (HERA) Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019
Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011
Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination can decrease mortality of COPD patients, a nationwide population-based cohort study in Taiwan Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
A case control study:The role of leukotriene receptor antagonist in cardiovascular risk Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Source: Eur Respir J 2008; 32: 1158-1164 Year: 2008
LATE-BREAKING ABSTRACT: Effect of QAW039, an oral prostaglandin D2 receptor (DP2/CRTh2) antagonist, upon bronchial epithelial integrity in treatment-resistant asthma in a randomized, placebo controlled study Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015
Effect of angiotensin II receptor antagonists on cardiovascular disorders in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 212s Year: 2001
Tachykinin 1 receptor antagonist FK888 suppresses angiotensin converting enzyme inhibitors (ACEIs)-induced tracheal inflammation, an experimental study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Association of cardiovascular risk with inhaled long-acting anti-muscarinic antagonists in COPD patients with impaired renal function Source: International Congress 2018 – Cardiovascular morbidities in COPD Year: 2018
Pirfenidone, proton pump inhibitor, N acetyl cysteine (PINPOINT) therapy for IPF: Tolerance and safety profile among Indian patients Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012
Impact of statins, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARBS) on reducing COPD morbidity Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Use of anti-inflammatory therapy and asthma mortality in Japan Source: Eur Respir J 2003; 21: 101-104 Year: 2003
Impact of glucagon-like peptide 1 receptor agonists on lung function of diabetic patients: a 52 weeks clinical trial Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018